Legend Biotech Corp
Close on Oct 19, 2026
- Market cap
- $6.89B
- P/E (TTM)
- –
- Dividend yield
- –
About Legend Biotech
Pharmaceutical Preparations, SIC 2834
Legend Biotech Corporation is a global biopharmaceutical enterprise that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other medical indications. Its lead commercial product is CARVYKTI (ciltacabtagene autoleucel), an autologous CAR-T cell therapy targeting B-cell maturation antigen, developed in partnership with Janssen for treating patients with relapsed or refractory multiple myeloma. In addition to cilta-cel, the company pursues an exploratory pipeline of autologous and allogeneic CAR-T and CAR-NK product candidates for solid tumors, hematologic malignancies, and autoimmune disorders. Its primary treatments serve adult cancer patients who have experienced disease progression following multiple prior lines of therapy.
The company operates internationally with approximately 2,900 employees located across the United States, China, and Europe. It maintains principal manufacturing and research and development facilities situated in the United States, Belgium, and China, enabling both clinical supply and commercial delivery across global markets. Legend Biotech Corporation maintains its principal executive offices in Somerset, New Jersey.
Summary of the business section of Legend Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Legend Biotech Corp
- Founded
- 2015
- Headquarters
- Somerset, NJ
- Address
- 2101 Cottontail Lane 08873
- Phone
- (732) 850-5598
- Website
- legendbiotech.com
- Employees
- 2,900, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- LEGN
- Exchange
- Nasdaq
- IPO date
- Jun 8, 2020
- Shares outstanding
- 370M, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1801198
- CUSIP
- 52490G102
- ISIN
- US52490G1022
- LEI
- 254900EIUFZTW136H859
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ying Huang | Chief Executive Officer, Director | 238,490 |
| Carlos E. Santos | Chief Financial Officer | 19,676 |
| Ingrid Zhang | Chief Executive Officer | 1,131,860 |
| Alan Bash | Interim CEO | 35,142 |
| Tomas J. Heyman | Director | 53,720 |
| Corazon (Corsee) D. Sanders | Director | 80,101 |
| Peter Salovey | Director | 55,096 |
| Patrick John Casey | Director | 69,590 |
| Darren Xiaohui Ji | Director | 92,103 |
| Li Mao | Director | 65,316 |
| Fangliang Zhang | Director | – |
| Ye Wang | Director | 16 |
| Robin Meng | Director | – |
| Gareth Kung | Director | 31,486 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 2,900 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 8, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 2, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |